- Johnson & Johnson continues to be a cornerstone of Ken Fisher (Trades, Portfolio)'s investment strategy with robust R&D investments.
- Analysts predict a potential upside of 8.42% with a strong "Outperform" rating.
- GuruFocus estimates a 19.83% upside based on GF Value calculations.
Johnson & Johnson (JNJ, Financial) remains a top-value stock in Ken Fisher (Trades, Portfolio)'s portfolio, boasting significant investments in research and development. With a dividend yield of 3.21% and strong performance from its CARVYKTI cancer treatment, the company anticipates continued growth despite global market uncertainties.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for Johnson & Johnson (JNJ, Financial) is $170.72, with estimates ranging from a high of $185.00 to a low of $150.00. This average target suggests a promising upside of 8.42% from the current price of $157.47. For a more comprehensive look at these estimates, visit the Johnson & Johnson (JNJ) Forecast page.
The consensus recommendation from 26 brokerage firms places Johnson & Johnson (JNJ, Financial) at an average brokerage recommendation of 2.3, indicating an "Outperform" status. The rating spectrum here extends from 1, which reflects a Strong Buy, to 5, indicating a Sell.
GuruFocus GF Value Estimate
According to GuruFocus estimates, the projected GF Value for Johnson & Johnson (JNJ, Financial) in one year is $188.69. This projection suggests a substantial upside of 19.83% from the current price of $157.47. The GF Value represents GuruFocus' calculation of the stock's fair trading value, considering its historical trading multiples, past business growth, and future business performance projections. For more detailed insights, please refer to the Johnson & Johnson (JNJ) Summary page.
